Nuveen
AARD icon

Nuveen’s Aardvark Therapeutics AARD Stock Holding History

Nuveen’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$761 Buy
+147
New +$897 ﹤0.01% 4953
2026
Q2 		– Sell
-15,312
Closed -$57.7K – 3863
2026
Q1 		$57.7K Sell
15,312
-25,710
-63% -$267K ﹤0.01% 3202
2025
Q4 		$538K Buy
+41,022
New +$512K ﹤0.01% 2843

Other funds holding AARD

Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57.1B AUM 43.46% 1-Year Est. Return

Nuveen's AARD Position: Q3 2026 in Review

Nuveen opened a new position in Aardvark Therapeutics (AARD) in Q3 2026: 147 shares worth $761. The stake represents ﹤0.01% of the portfolio and ranks #4953 among its holdings. This is a return to the name: Nuveen previously reported a position in AARD as recently as Q1 2026.

Nuveen first reported a position in AARD in Q4 2025 and has held it in 3 quarters since. The position peaked at $538K in Q4 2025. 26 funds tracked by Wall St. Rank hold AARD as of Q3 2026.

  • Nuveen held 147 shares of Aardvark Therapeutics worth $761 as of Q3 2026.
  • Aardvark Therapeutics was a new Nuveen position in Q3 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4953 holding.
  • Nuveen first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Nuveen's Aardvark Therapeutics position peaked at $538K in Q4 2025.
  • 26 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.